These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 1691160)
21. Primary central nervous system lymphoma in Japan: a nationwide survey. Hayabuchi N; Shibamoto Y; Onizuka Y Int J Radiat Oncol Biol Phys; 1999 May; 44(2):265-72. PubMed ID: 10760418 [TBL] [Abstract][Full Text] [Related]
22. Primary Mediastinal B-cell lymphoma with sclerosis: clinical and therapeutic evaluation of 22 patients. Zinzani PL; Bendandi M; Frezza G; Gherlinzoni F; Merla E; Salvucci M; Magagnoli M; Babini L; Tura S Leuk Lymphoma; 1996 Apr; 21(3-4):311-6. PubMed ID: 8726412 [TBL] [Abstract][Full Text] [Related]
23. Treatment of diffuse non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone and bleomycin (MACOP-B). Sawada U; Yamazaki T; Suzuki K; Ashiya M; Satou Y; Hirano H; Tsuboi I; Sakuma A; Kura Y; Kouda K Int J Hematol; 1992 Aug; 56(1):59-66. PubMed ID: 1382663 [TBL] [Abstract][Full Text] [Related]
24. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study. Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168 [TBL] [Abstract][Full Text] [Related]
25. Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy. Bessell EM; Graus F; Punt JA; Firth JL; Hope DT; Moloney AJ; Lopez-Guillermo A; Villa S J Clin Oncol; 1996 Mar; 14(3):945-54. PubMed ID: 8622044 [TBL] [Abstract][Full Text] [Related]
26. Systemic chemotherapy with vincristine, cyclophosphamide, doxorubicin and prednisolone following radiotherapy for primary central nervous system lymphoma: a phase II study. Shibamoto Y; Sasai K; Oya N; Hiraoka M J Neurooncol; 1999 Apr; 42(2):161-7. PubMed ID: 10421074 [TBL] [Abstract][Full Text] [Related]
27. MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas. Mazza P; Zinzani PL; Martelli M; Fiacchini M; Bocchia M; Pileri S; Falini B; Martelli MF; Amadori S; Papa G Leuk Lymphoma; 1995 Feb; 16(5-6):457-63. PubMed ID: 7540460 [TBL] [Abstract][Full Text] [Related]
28. [Clinical outcomes in low grade follicular lymphoma]. Yamazaki T; Kura Y; Sato Y; Irie T; Kaneita Y; Mochimaru J; Hanai M; Yasukawa K; Sawada U; Horie T Rinsho Ketsueki; 1999 Jan; 40(1):1-8. PubMed ID: 10067089 [TBL] [Abstract][Full Text] [Related]
29. Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. Derenzini E; Stefoni V; Pellegrini C; Fina MP; Broccoli A; Venturini F; Gandolfi L; Pileri SA; Martelli M; Petti MC; Perrotti A; De Renzo A; Zaja F; Baccarani M; Zinzani PL Leuk Lymphoma; 2009 Nov; 50(11):1824-9. PubMed ID: 19814687 [TBL] [Abstract][Full Text] [Related]
30. A follow-up of a randomized study comparing two chemotherapy treatments for advanced diffuse histiocytic lymphoma. Todd M; Cadman E; Spiro P; Bertino J; Farber L; Waldron J; Fischer D J Clin Oncol; 1984 Sep; 2(9):986-93. PubMed ID: 6206207 [TBL] [Abstract][Full Text] [Related]
31. Is there a role for MACOP-B in the treatment of diffuse large cell lymphoma? O'Reilly SE; Connors JM Leuk Lymphoma; 1993; 10 Suppl():85-9. PubMed ID: 7683229 [TBL] [Abstract][Full Text] [Related]
32. Conservative management of primary cervical lymphoma using combination chemotherapy: a case report. Johnston C; Senekjian EK; Ratain MJ; Talerman A Gynecol Oncol; 1989 Dec; 35(3):391-4. PubMed ID: 2480933 [TBL] [Abstract][Full Text] [Related]
33. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Todeschini G; Secchi S; Morra E; Vitolo U; Orlandi E; Pasini F; Gallo E; Ambrosetti A; Tecchio C; Tarella C; Gabbas A; Gallamini A; Gargantini L; Pizzuti M; Fioritoni G; Gottin L; Rossi G; Lazzarino M; Menestrina F; Paulli M; Palestro M; Cabras MG; Di Vito F; Pizzolo G Br J Cancer; 2004 Jan; 90(2):372-6. PubMed ID: 14735179 [TBL] [Abstract][Full Text] [Related]
34. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536 [TBL] [Abstract][Full Text] [Related]
35. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442 [TBL] [Abstract][Full Text] [Related]
36. Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. Wolf M; Matthews JP; Stone J; Cooper IA; Robertson TI; Fox RM Ann Oncol; 1997; 8 Suppl 1():71-5. PubMed ID: 9187435 [TBL] [Abstract][Full Text] [Related]
37. The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients. Broccoli A; Casadei B; Stefoni V; Pellegrini C; Quirini F; Tonialini L; Morigi A; Marangon M; Argnani L; Zinzani PL BMC Cancer; 2017 Apr; 17(1):276. PubMed ID: 28415982 [TBL] [Abstract][Full Text] [Related]
38. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas. Schneider AM; Straus DJ; Schluger AE; Lowenthal DA; Koziner B; Lee BJ; Wong G; Clarkson BD J Clin Oncol; 1990 Jan; 8(1):94-102. PubMed ID: 1688617 [TBL] [Abstract][Full Text] [Related]
39. MACOP-B +/- radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford results according to prognostic indices. Bartlett NL; Kwak LW; Horning SJ Cancer; 1993 Jun; 71(12):4034-42. PubMed ID: 7685238 [TBL] [Abstract][Full Text] [Related]